Vés al contingut

A phase IIb, multicentre, randomised, double-blind, placebo controlled, crossover study to evaluate the efficacy and safety of Dirocaftor/Posenacaftor/Nesolicaftor in subjects with cystic fibrosis aged 18 years or older (CHOICES)

Obert
  • Codi protocol: HIT-CF-001
  • Codi EudraCT: _
  • Grup de recerca: Pneumologia
  • Servei: Pneumologia
  • Investigador/a principal:  Álvarez Fernandez, Antonio
  • Malaltia: Malalties del sistema respiratori
  • Fase: Fase II